ArticleMovement disorders : official journal of the Movement Disorder Society2016
Identification of bona-fide LRRK2 kinase substrates.
Article in Movement disorders : official journal of the Movement Disorder Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- CalDAG-GEFI acts as a guanine nucleotide exchange factor for LRRK2 to regulate LRRK2 function and neurodegeneration.Science advances · 2024Article
- Primary cilia and SHH signaling impairments in human and mouse models of Parkinson's disease.Nature communications · 2022Article
- LRRK2 binds to the Rab32 subfamily in a GTP-dependent mannerSmall GTPases · 2021Article
- Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.International journal of molecular sciences · 2021Review
- Phosphorylation of Rab GTPases in the regulation of membrane trafficking.Traffic (Copenhagen, Denmark) · 2020Article
- Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2.Structure (London, England : 1993) · 2020Article
- Profiling Non-motor Symptoms in Monogenic Parkinson's Disease.Frontiers in aging neuroscience · 2020Review
- Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.Experimental neurology · 2017Review
- LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.Molecular therapy. Nucleic acids · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.